Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs

Table 1 Demographics and treatment history for eight male cases

Case	Race	Age	Genotype	Test to diagnose cirrhosis	IL-28b	Total number of times treated (including DAAs)	Number of times treated with PEG/RBV dual therapy	Prior PI treatment	Time interval between PI and SMV/SOF (mo)	Viral load prior to SMV/SOF treatment (IU/mL)	RBV used with SM/SOF	Duration of treatment (wk)
1	White	60	1a	Fibroscan (24 kPa)	CT	5	3	TVR	30	1449160	Yes	12
2	White	49	1b	Fibroscan (33.3 kPa)	Unknown	3	0	TVR, BOC	19	180020	Yes	12
3	White	54	1a	Fibroscan (32.8 kPa)	Unknown	4	2	TVR	26	10349963	Yes	12
4	African American	50	1a	MRI	TT	4	2	TVR	25	7753010	Yes	12
5	White	63	1a	Fibroscan (34.3 kPa)	Unknown	4	1	TVR, BOC	12	8450674	Yes	12
6	White	53	1a	MRI	Unknown	3	1	TVR	--	2429839	No	12
7	White	64	1a	MRI	Unknown	3	1	TVR	28	5448450	Yes	12
8	African American	54	1a	Fibroscan (26.3 kPa)	Unknown	6	4	TVR	31	3108263	Yes	12

DAA: Direct acting antiviral; PEG: Pegylated-interferon; RBV: Ribavirin; PI: Protease inhibitor; SOF: Sofosbuvir; SMV: Simeprevir; TVR: Telaprevir; BOC: Boceprevir; CT: Computed tomography; MRI: Magnetic resonance imaging.